Cytokinetics (CYTK) Q3 2026 earnings summary

Executive summary

• MYQORZO net product revenue reached $44.5M in Q3, up 76% QoQ; total revenue was $47.6M.

• Positive ACACIA-HCM results supported plans for a U.S. nHCM sNDA in Q4 2026 and an EU application in early 2027.

• Cash, cash equivalents and investments totaled $1.58B at September 30, 2026; FY 2026 expense guidance was reaffirmed.

Financial highlights

• Q3 revenue was $47.6M versus $1.9M YoY, including $44.5M MYQORZO product revenue and $3.1M collaboration revenue; 9M revenue was $95.5M versus $70.3M.

• Q3 R&D expense was $99.3M versus $97.3M YoY; SG&A was $113.1M versus $69.5M, reflecting clinical activity, launch costs and personnel.

• Q3 net loss was $190.1M, or $1.37/share, versus $306.2M, or $2.55/share; 9M net loss was $594.9M.

• Q3 operating loss was $167.1M versus $166.8M YoY; 9M operating loss was $529.9M versus $433.9M.

Outlook and guidance

• FY 2026 GAAP combined R&D and SG&A expense guidance was reaffirmed at $860M-$890M, including $130M-$140M in expected stock-based compensation.

• MYQORZO’s U.K. launch is expected in Q4 2026; additional country launches are planned in 2027.

• Aficamten’s nHCM sNDA is on track for Q4 2026; an EU application is expected in early 2027. MAPLE-HCM’s sNDA has a November 14, 2026 PDUFA date.

• CEDAR-HCM adolescent topline results are expected in early 2027; AMBER-HFpEF cohort one enrollment is expected to finish in Q4 2026, while COMET-HF enrollment continues through 2027.

• Existing cash, investments and investment interest are expected to fund projected operating requirements for at least 12 months after the report date.